Cargando…

Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey

BACKGROUND: During COVID-19, the Substance Abuse and Mental Health Services Administration (SAMHSA) allowed Methadone Maintenance Treatment (MMT) programs to relax in-person MMT requirements to reduce COVID-19 exposure. This study examines patient-reported changes to in-person methadone clinic atten...

Descripción completa

Detalles Bibliográficos
Autores principales: Brothers, Sarah, Palayew, Adam, Simon, Caty, Coulter, Abby, Strichartz, Knina, Voyles, Nick, Vincent, Louise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996563/
https://www.ncbi.nlm.nih.gov/pubmed/36894968
http://dx.doi.org/10.1186/s12954-023-00756-3
_version_ 1784903071375032320
author Brothers, Sarah
Palayew, Adam
Simon, Caty
Coulter, Abby
Strichartz, Knina
Voyles, Nick
Vincent, Louise
author_facet Brothers, Sarah
Palayew, Adam
Simon, Caty
Coulter, Abby
Strichartz, Knina
Voyles, Nick
Vincent, Louise
author_sort Brothers, Sarah
collection PubMed
description BACKGROUND: During COVID-19, the Substance Abuse and Mental Health Services Administration (SAMHSA) allowed Methadone Maintenance Treatment (MMT) programs to relax in-person MMT requirements to reduce COVID-19 exposure. This study examines patient-reported changes to in-person methadone clinic attendance requirements during COVID-19. METHODS: From June 7, 2020, to July 15, 2020, a convenience sample of methadone patients (N = 392) were recruited in collaboration with National Survivors Union (NSU) in 43 states and Washington D.C. through social media (Facebook, Reddit, Twitter, and Web site pop-ups). The community-driven research (CDR) online survey collected information on how patient take-home methadone dosing and in-person drug testing, counseling, and clinic visit frequency changed prior to COVID-19 (before March 2020) to during COVID-19 (June and July 2020). RESULTS: During the study time period, the percentage of respondents receiving at least 14 days of take-home doses increased from 22 to 53%, while the percentage receiving one or no take-home doses decreased from 22.4% before COVID-19 to 10.2% during COVID-19. In-person counseling attendance decreased from 82.9% to 19.4%. While only 3.3% of respondents accessed counseling through telehealth before COVID-19, this percentage increased to 61.7% during COVID-19. Many respondents (41.3%) reported visiting their clinics in person once a week or more during COVID-19. CONCLUSIONS: During the first wave of COVID-19, methadone patients report decreased in-person clinic attendance and increased take-home doses and use of telehealth for counseling services. However, respondents reported considerable variations, and many were still required to make frequent in-person clinic visits, which put patients at risk of COVID-19 exposure. Relaxations of MMT in-person requirements during COVID-19 should be consistently implemented and made permanent, and patient experiences of these changes should be explored further.
format Online
Article
Text
id pubmed-9996563
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99965632023-03-09 Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey Brothers, Sarah Palayew, Adam Simon, Caty Coulter, Abby Strichartz, Knina Voyles, Nick Vincent, Louise Harm Reduct J Research BACKGROUND: During COVID-19, the Substance Abuse and Mental Health Services Administration (SAMHSA) allowed Methadone Maintenance Treatment (MMT) programs to relax in-person MMT requirements to reduce COVID-19 exposure. This study examines patient-reported changes to in-person methadone clinic attendance requirements during COVID-19. METHODS: From June 7, 2020, to July 15, 2020, a convenience sample of methadone patients (N = 392) were recruited in collaboration with National Survivors Union (NSU) in 43 states and Washington D.C. through social media (Facebook, Reddit, Twitter, and Web site pop-ups). The community-driven research (CDR) online survey collected information on how patient take-home methadone dosing and in-person drug testing, counseling, and clinic visit frequency changed prior to COVID-19 (before March 2020) to during COVID-19 (June and July 2020). RESULTS: During the study time period, the percentage of respondents receiving at least 14 days of take-home doses increased from 22 to 53%, while the percentage receiving one or no take-home doses decreased from 22.4% before COVID-19 to 10.2% during COVID-19. In-person counseling attendance decreased from 82.9% to 19.4%. While only 3.3% of respondents accessed counseling through telehealth before COVID-19, this percentage increased to 61.7% during COVID-19. Many respondents (41.3%) reported visiting their clinics in person once a week or more during COVID-19. CONCLUSIONS: During the first wave of COVID-19, methadone patients report decreased in-person clinic attendance and increased take-home doses and use of telehealth for counseling services. However, respondents reported considerable variations, and many were still required to make frequent in-person clinic visits, which put patients at risk of COVID-19 exposure. Relaxations of MMT in-person requirements during COVID-19 should be consistently implemented and made permanent, and patient experiences of these changes should be explored further. BioMed Central 2023-03-09 /pmc/articles/PMC9996563/ /pubmed/36894968 http://dx.doi.org/10.1186/s12954-023-00756-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Brothers, Sarah
Palayew, Adam
Simon, Caty
Coulter, Abby
Strichartz, Knina
Voyles, Nick
Vincent, Louise
Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey
title Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey
title_full Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey
title_fullStr Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey
title_full_unstemmed Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey
title_short Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey
title_sort patient experiences of methadone treatment changes during the first wave of covid-19: a national community-driven survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996563/
https://www.ncbi.nlm.nih.gov/pubmed/36894968
http://dx.doi.org/10.1186/s12954-023-00756-3
work_keys_str_mv AT brotherssarah patientexperiencesofmethadonetreatmentchangesduringthefirstwaveofcovid19anationalcommunitydrivensurvey
AT palayewadam patientexperiencesofmethadonetreatmentchangesduringthefirstwaveofcovid19anationalcommunitydrivensurvey
AT simoncaty patientexperiencesofmethadonetreatmentchangesduringthefirstwaveofcovid19anationalcommunitydrivensurvey
AT coulterabby patientexperiencesofmethadonetreatmentchangesduringthefirstwaveofcovid19anationalcommunitydrivensurvey
AT strichartzknina patientexperiencesofmethadonetreatmentchangesduringthefirstwaveofcovid19anationalcommunitydrivensurvey
AT voylesnick patientexperiencesofmethadonetreatmentchangesduringthefirstwaveofcovid19anationalcommunitydrivensurvey
AT vincentlouise patientexperiencesofmethadonetreatmentchangesduringthefirstwaveofcovid19anationalcommunitydrivensurvey